Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
HIV: early-phase trial registry
109 of 304 indexed HIV trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #27 of 28,707 conditions by registered trial count.
304 US clinical trials · 109 currently recruiting · #27 of 28,707 conditions by registered trial count
HIV: 304 US clinical trials tracked, 109 recruiting.
HIV is the subject of 304 registered US clinical trials on ClinicalTrials.gov, 109 of them currently open to new participants. 25 are in Phase 3-4 (later-stage) and 64 in Phase 1-2 (earlier-stage). The most active sponsor is National Institute of Allergy and Infectious Diseases (NIAID), running 24 of these trials.
Enrollment posture brief
Registry condition hiv
OPEN 109 | RECR 36% | LATE 25 | EARLY 64 | RANK #27 | SPON 24
Volume-matched condition peers
Nearest open-share peer: Acute Respiratory Failure (36% recruiting · 14 trials)
HIV lists 109 open slots (36% of 304 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for HIV on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
HIV recruits in line with its size-band peers.
109 of 304 indexed trials (35.9%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of HIV trials is spread across many organizations.
National Institute of Allergy and Infectious Diseases (NIAID) accounts for 24 of 304 trials (7.9%). 115 distinct sponsors appear on at least one study for this condition label.
-
Typical HIV enrolment sits around 100 participants.
Median target enrolment is 100 among the 304 trials that report a genuine target (sentinel values excluded). 142 of those (46.7%) plan for fewer than 100 participants.
-
HIV research is mostly interventional.
252 interventional and 52 observational studies make up this index (82.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
304 total, page 6 of 7
Cognitive Behavior Therapy (CBT)-Based Group Intervention to Reduce Inflammation in Older People With HIV
Massachusetts General Hospital
NCT05434741
Increasing Motivation for Antiretroviral Therapy Initiation: A Pilot Intervention
University of Maryland, Baltimore
NCT02055417
A Phase 1, Open Label, Dose-escalation Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 3BNC117
Rockefeller University
NCT02018510
Rifaximin for Chronic Immune Activation in People With HIV
National Cancer Institute (NCI)
NCT01866826
Lower Extremity Splinting to Manage Pain and Sleep Disturbances Associated With HIV/AIDS Related Peripheral Neuropathy
Texas Woman's University
NCT01419314
Exercise and Pioglitazone for HIV-Metabolic Syndromes
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT00639457
A Clinical Trial to Evaluate Safety, Tolerability, and Immunogenicity of Adjuvanted HIV-1 Fusion Peptide Conjugate Vaccine Alone or in Prime-Boost Regimens With Adjuvanted HIV-1 Envelope Trimer 4571 and HIV-1 Trimer 6931 Vaccines in Healthy Adults
National Institute of Allergy and Infectious Diseases (NIAID)
NCT05470400
Effect of Gender and HIV Infection on Zidovudine and Lamivudine Pharmacokinetics
University of Colorado, Denver
NCT01386970
Development of an Empowerment Intervention for Young Women Living With HIV
University of North Carolina, Chapel Hill
NCT01454921
Treatment for Depression Among HIV-Infected Youth
University of North Carolina, Chapel Hill
NCT01049789
Neurocognitive Effects of Buprenorphine Among HIV+ and HIV-Opioid Users
Albert Einstein College of Medicine
NCT01108679
Safety and Efficacy of Salsalate to Treat Endothelial Dysfunction in HIV-infected Adults
University Hospitals Cleveland Medical Center
NCT01046682
Technology-Enhanced Peer Navigation to Improve IDUs' Engagement in HIV Care
Johns Hopkins Bloomberg School of Public Health
NCT01941108
Safety, Tolerability, and Effect of TMC207 and Efavirenz in Healthy Volunteers
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00992069
Validation of a Urine Assay to Measure Tenofovir Levels in Patients Taking Tenofovir Alafenamide
Philadelphia Fight
NCT03350672
Contingency Management in HIV Care for Both Stimulant Use & ART Adherence
University of California, San Francisco
NCT06564792
Adapting the Finding Respect and Ending Stigma Around HIV (FRESH) Intervention for the Dominican Republic
Florida State University
NCT04491539
PET/CT Imaging Companion Study To ACTG A5314
Massachusetts General Hospital
NCT02312219
Safety, Pharmacokinetics and Acceptability of PC-1005 for Vaginal Use
Population Council
NCT02033109
Pilot Study of the Effects of Exercise on Aging Among Older Persons With HIV
University of California, San Francisco
NCT01860261
Strength Training and Endurance Exercise for LIFE
VA Office of Research and Development
NCT02101060
A Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 10-1074
Rockefeller University
NCT02511990
Improving Memory Performance by Applying Cognitive Training
Duke University
NCT02216591
NOLA GEM: Feasibility and Acceptability of an MHealth Intervention for Violence-affected PLWH
Tulane University
NCT05784714
SmartManage Stress Management for HIV+ Cancer Survivors
University of Miami
NCT04544917
Exploring HIV Entry Blockade as a Pre-exposure Prophylaxis Strategy in Women
Emory University
NCT01749566
CBSM Intervention Via mHealth to Ameliorate HIV-related Fatigue
Medical University of South Carolina
NCT03149094
CRUSH-PrEP for Women Project
University of California, San Francisco
NCT02852226
Development of a Urine-Based Point-of-Care Test for Adherence to Antiretroviral Drugs
Rhonda Brand
NCT04302896
Use of 99mTc Tilmanocept for Imaging Arterial Inflammation
Massachusetts General Hospital
NCT02542371
Impact of a Short-Term Analytical Treatment Interruption and Re-Initiation of Antiretroviral Therapy on Immunologic and Virologic Parameters in HIV-Infected Individuals
National Institute of Allergy and Infectious Diseases (NIAID)
NCT03225118
Developing a Trauma-focused Intervention for Older Adults Living With HIV
University of South Carolina
NCT05287230
Y2Prevent: Preventing Drug Use and HIV Through Empowerment, Social Support and Mentorship (Y2P)
Children's Hospital Los Angeles
NCT04504981
Potential for Drug-drug Interactions Between Boceprevir and Etravirine in HIV/Hepatitis C Virus Negative Volunteers
University of Colorado, Denver
NCT01427504
Effects of Biktarvy on CFR in Stable HIV Patients
Brigham and Women's Hospital
NCT03656783
N-acetylcysteine to Reduce Oxidative Stress and Improve Endothelial Function in HIV-infected Older Adults
Indiana University
NCT01962961
Randomized Placebo-Controlled Trial of Atorvastatin in HIV-Positive Patients Not on Antiretroviral Therapy
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00367458
Examining Hair to Determine Tenofovir Exposure
Public Health Foundation Enterprises
NCT00903084
Effects of Using E-Cigarettes on Lungs in People With HIV (HBS Ancillary)
Pennington Biomedical Research Center
NCT04794543
Supervised Treadmill Intervention to Reduce Inflammation and Depression Through Exercise in HIV: The STRIDE Pilot Study
University of Minnesota
NCT06149624
Changes in Lipids and Safety of Raltegravir in HIV+ Patients With Hyperlipidemia While on Current Standard Therapy
The Miriam Hospital
NCT00887653
Interluekin-7 to Treat HIV-Infected People Receiving Antiretroviral Treatment
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00105417
BK Virus in Salivary Gland Disease: Treating the Potential Etiologic Agent
University of North Carolina, Chapel Hill
NCT02068846
Safety, PK, and PD Study of a Vaginal Insert Containing TAF and EVG
CONRAD
NCT03762772
Distress Tolerance and HIV Prevention With XR-NTX Initiation in Opioid Dependence
Rhode Island Hospital
NCT02602795
A Phase I Study to Evaluate the Safety and Immunogenicity of Heterologous Boost Immunizations With MVA-CMDR
Rockefeller University
NCT01889719
ARCH II Study (Alcohol Research Center on HIV Study II)
University of Florida
NCT02563574
Taste Assessment Study of 2 Atazanavir Powder Formulations in Healthy Subjects
Bristol-Myers Squibb
NCT01404572
Proof of Principle Study of Pulse Dosing of IL-15 to Deplete the Reservoir in HIV Infected People
University of Minnesota
NCT02191098
A Phase 1 Trial to Evaluate CAP256V2LS in Healthy Adults
National Institute of Allergy and Infectious Diseases (NIAID)
NCT04408963
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 32 |
| Phase 2 | 32 |
| Phase 3 | 12 |
| Phase 4 | 13 |
Top Sponsors
Named interventions
Most-linked intervention names on HIV records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on HIV trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this HIV page
304 registered trials, 109 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 109 HIV trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Institute of Allergy and Infectious Diseases (NIAID) sponsors the most HIV trials on record, review their full trial history before evaluating a specific study. See National Institute of Allergy and Infectious Diseases (NIAID)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This HIV condition card totals 304 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.